<DOC>
	<DOCNO>NCT00653913</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetic interaction safety coadministration SCH 58235 ( ezetimibe ) pitavastatin healthy Japanese adult male subject adult male subject obvious disease high cholesterol level .</brief_summary>
	<brief_title>Evaluation Potential Drug Interaction Between SCH 58235 ( Ezetimibe ) Pitavastatin ( Study P03962 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Healthy adult male subject meet criterion adult male subject obvious disease high cholesterol level . Aged 20 year 65 year informed consent obtain . Weighing 50 kg 80 kg day screen test , BMI [ Body Mass Index : body weight ( kg ) /height ( ) 2 ] range 16.5 27.5 . Patients meet one follow condition exclude study . Subjects triglyceride value screen test exceed 500 mg/dL . Subjects past history drug allergy ( shock , anaphylactic symptom , angioedema ) . Subjects past history alcohol drug dependence . Subjects past history mental disorder . Subjects positive test HBs antigen , HCV antibody , HIV antibody serological test syphilis . Subjects use drug within 2 week investigational product administration Period 1 . Subjects draw 400 mL blood within 12 week administration day Period 1 . Subjects participate study within 16 week investigational product administration Period 1 administer investigational product . Subjects take contraceptive measure study period ( provide inform consent completion Period 3 examination ) Subjects investigator judge inappropriate participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>